News coverage about GlycoMimetics (NASDAQ:GLYC) has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.7151330825177 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of equities analysts recently commented on GLYC shares. Jefferies Group reiterated a “buy” rating and set a $16.00 price target on shares of GlycoMimetics in a report on Thursday, October 26th. Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Monday, November 13th. BidaskClub upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Cowen reiterated a “buy” rating on shares of GlycoMimetics in a report on Wednesday, December 6th. Finally, SunTrust Banks lifted their price target on GlycoMimetics to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $22.67.
Shares of GlycoMimetics (NASDAQ GLYC) opened at $24.04 on Wednesday. GlycoMimetics has a 1-year low of $3.82 and a 1-year high of $26.05. The stock has a market capitalization of $858.79, a P/E ratio of -19.39 and a beta of 3.40.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.